Holen Sie sich die Stockscreener-App
26.45
0.57%
0.15
Handel nachbörslich:
26.50
0.05
+0.19%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Tunica-Biloxi Tribe receives grant from Pfizer to expand healthcare in Central Louisiana - WKRG
Pfizer Quarterly Results Announcement: Revenue Forecasts and Market Sentiment | May 2026News and Statistics - IndexBox
Pfizer Earnings Call Highlights Growth Beyond COVID - TipRanks
Pfizer Gains Attention In Russell 1000 Index Momentum - Kalkine Media
Pfizer’s First PROTAC Approval Adds New Dimension To Oncology Story - simplywall.st
Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC - marketscreener.com
Pfizer Oncology Advances Raise New Questions For Valuation And Momentum - Yahoo Finance
Pfizer Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Pfizer CEO Says Digging Out of Post-Covid Hole Will Take a Few More Years -- WSJ - Moomoo
Pfizer Earnings: Strong First-Quarter Performance Makes 2026 Guidance More Achievable - Morningstar
BofA raises Pfizer stock price target on first-quarter beat By Investing.com - Investing.com Canada
BofA raises Pfizer stock price target on first-quarter beat - Investing.com
Pfizer CEO Sees CDC Director Pick Restoring Agency’s Credibility - Bloomberg
Pfizer Beats Earnings Estimates. The Drugmaker Is Finding Life After Covid. - Barron's
PFIZER INC : JP Morgan reaffirms its Neutral rating - marketscreener.com
Pfizer Beats Sales Estimates As $17 Billion Patent Cliff Looms - GuruFocus
Pfizer pins post 2028 return to growth on new obesity and cancer drugs - Yahoo! Finance Canada
Research Alert: CFRA Lowers Rating On Shares Of Pfizer Inc. To Hold From Buy - Moomoo
Pfizer Q1 2026 slides: beats estimates on acquired assets strength - Investing.com
Pfizer Beats on Q1 Earnings, New & Acquired Drugs Drive Sales Growth - Yahoo Finance
Pfizer tops Q1 expectations on growth from newer products - MSN
Earnings call transcript: Pfizer Q1 2026 beats estimates, stock rises - Investing.com
Pfizer Says Vyndamax Drug Patent Settlement Reshapes Post-2028 Revenue View - Benzinga
Pfizer Q1 Earnings Review: Stuck In Second Gear, But Dividend Helps (NYSE:PFE) - Seeking Alpha
Pfizer : Quarterly Corporate PerformanceFirst Quarter 2026 Presentation - marketscreener.com
Pfizer Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:PFE) 2026-05-05 - Seeking Alpha
Pfizer Tops First-Quarter Estimates, Reaffirms Full-Year Outlook - Moomoo
2 Trendlines in Focus For Pfizer Stock After Earnings - Schaeffer's Investment Research
Pfizer beats first quarter estimates on strong product growth - Investing.com
Pfizer tops sales estimates as older blockbusters outperform - Crain's New York Business
Pfizer (PFE) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Pfizer Inc. Reports Earnings Results for the First Quarter Ended March 29, 2026 - marketscreener.com
Pfizer (PFE) Stock Climbs as Eliquis Drives Strong Q1 Earnings Performance - MEXC
Pfizer (PFE) Stock: Blood Thinner Eliquis Helps Deliver a Clean Q1 Earnings Beat - MEXC Exchange
Pfizer Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Pfizer Posts Better-Than-Expected Revenue, Profit - WSJ
Pfizer Q1 2026 earnings beat estimates on newer drug growth - Yahoo Finance
Pfizer beats Q1 revenue and profit estimates, reaffirms 2026 guidance - Proactive financial news
Pfizer Releases Q1 2026 Financial Results - AlphaStreet
Pfizer posts strong first-quarter earnings, sees boost from recent court wins - Reuters
Pfizer (NYSE:PFE) Posts Better-Than-Expected Sales In Q1 CY2026 - Yahoo Finance
Pfizer Q1 Earnings Exceed Expectations - Intellectia AI
Pfizer CEO on his mom not hiding her Holocaust story - CNN
Pfizer (PFE) Q1 Earnings and Revenues Top Estimates - Yahoo Finance Australia
Pfizer 1Q Revenue Rises But Profit Falls Amid Boosted R&D Spending - marketscreener.com
Pfizer Q1 Adjusted Earnings Fall, Revenue Rises - marketscreener.com
Pfizer Inc. (NYSE:PFE) Tops Q1 2026 Estimates Amid Strong Non-COVID Growth - ChartMill
Pfizer beats first quarter estimates on strong product growth By Investing.com - Investing.com South Africa
Pfizer tops Q1 estimates, maintains guidance (PFE:NYSE) - Seeking Alpha
(PFE) Pfizer Expects 2026 Revenue Range $59.5B to $62.5B, vs. FactSet Est of $61.38B - marketscreener.com
Earnings Flash (PFE) Pfizer Inc. Reports Q1 Revenue $14.45B, vs. FactSet Est of $13.84B - marketscreener.com
Earnings Flash (PFE) Pfizer Inc. Posts Q1 Adjusted EPS $0.75 per Share, vs. FactSet Est of $0.72 - marketscreener.com
Pfizer beats first-quarter profit estimates on strong demand for older drugs - marketscreener.com
Pfizer posts Q1 2026 revenue $14.45B, adjusted diluted EPS $0.75; reaffirms 2026 guidance - TradingView
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026 - GlobeNewswire Inc.
Pfizer: Q1 Earnings Snapshot - KTVB
Pfizer Tops Sales Estimates as Older Blockbusters Outperform - Bloomberg
Pfizer beats first-quarter profit estimates on strong demand for blood thinner Eliquis - Yahoo Finance
Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance - Business Wire
3 Dividend Stocks for May 2026 - Morningstar
Pfizer, Pinterest And 3 Stocks To Watch Heading Into TuesdayPfizer (NYSE:PFE) - Benzinga
Pfizer Earnings: What To Look For From PFE - Yahoo Finance
Watch Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC - Bloomberg
AMD and Pfizer earnings, job openings, Fedspeak: What to Watch - Yahoo Finance
Pfizer (PFE) Prepares for Q1 Earnings Amid Optimism on Growth Pr - GuruFocus
Pfizer Inc (PFE) Stock Price, Trades & News - GuruFocus
How To Earn $500 A Month From Pfizer Stock Ahead Of Q1 Earnings - Yahoo Finance
How Pfizer's CEO says he uses AI to make decisions - CNN
Jim Cramer on Pfizer: “If I Want Good Yield, I’ll Buy a Bond” - Insider Monkey
Pfizer earnings in focus as investors eye pipeline, patent cliff By Investing.com - Investing.com
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):